Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Agenus Inc
(NQ:
AGEN
)
6.560
+0.600 (+10.07%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Agenus Inc
< Previous
1
2
3
Next >
Agenus Reports Third Quarter 2023 Results
November 07, 2023
From
Agenus Inc.
Via
Business Wire
Agenus to Provide Third Quarter 2023 Financial Report and Corporate Update
October 26, 2023
From
Agenus Inc.
Via
Business Wire
Agenus Unveils New and Updated Botensilimab Data in Colorectal, Pancreatic, Lung, Melanoma, and Sarcoma
October 22, 2023
From
Agenus Inc.
Via
Business Wire
ESMO 2023: Agenus’ Botensilimab/Balstilimab Combination Delivers Durable Responses across Multiple Sarcoma Subtypes
October 21, 2023
From
Agenus Inc.
Via
Business Wire
Agenus Completes Enrollment in Randomized Phase 2 Clinical Trial of Botensilimab/Balstilimab in Advanced Colorectal Cancer
October 10, 2023
From
Agenus Inc.
Via
Business Wire
Agenus To Host BOT/BAL Program Update at ESMO 2023
October 05, 2023
From
Agenus Inc.
Via
Business Wire
Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 01, 2023
From
Agenus Inc.
Via
Business Wire
Agenus to Participate in September Investor Conferences
August 28, 2023
From
Agenus Inc.
Via
Business Wire
Agenus Prioritizes Resources to Accelerate Registration and Commercialization of BOT/BAL Program in Multiple Cancers
August 23, 2023
From
Agenus Inc.
Via
Business Wire
SaponiQx Announces Breakthrough in Scaling Up of STIMULON™ Cultured Plant Cell Adjuvant
August 09, 2023
From
SaponiQx
Via
Business Wire
Agenus Reports Second Quarter 2023 Results
August 08, 2023
From
Agenus Inc.
Via
Business Wire
Agenus Botensilimab/Balstilimab Data Update in Sarcomas Selected for Oral Presentation at ESMO 2023
July 28, 2023
From
Agenus Inc.
Via
Business Wire
Agenus to Provide Second Quarter 2023 Financial Report and Corporate Update
July 26, 2023
From
Agenus
Via
Business Wire
Agenus Expands Executive Leadership Team
July 20, 2023
From
Agenus Inc.
Via
Business Wire
ESMO GI Data: Agenus' Botensilimab/Balstilimab Combination Achieves Unprecedented Survival in Advanced Colorectal Cancer
June 30, 2023
From
Agenus
Via
Business Wire
Agenus Presents Positive Efficacy and Safety Outcomes for AGEN2373 at ASCO
June 05, 2023
From
Agenus Inc.
Via
Business Wire
Agenus Announces Virtual Annual Shareholders Meeting
June 05, 2023
From
Agenus
Via
Business Wire
Agenus to Participate in Jefferies Healthcare Conference
May 25, 2023
From
Agenus
Via
Business Wire
Agenus Provides Corporate Update and First Quarter 2023 Financial Results
May 09, 2023
From
Agenus Inc.
Via
Business Wire
Agenus Selected for Late-Breaking Oral Presentation at ESMO-GI
May 03, 2023
From
Agenus
Via
Business Wire
Agenus (NASDAQ: AGEN) Featured in Coverage of the Inaugural EF Hutton Global Conference
May 02, 2023
Via
Investor Brand Network
Agenus to Present at the American Society of Clinical Oncology 2023 Annual Meeting
April 26, 2023
From
Agenus
Via
Business Wire
Agenus to Provide Corporate Update and First Quarter 2023 Financial Report
April 25, 2023
From
Agenus
Via
Business Wire
Agenus to Participate in May Investor Conferences
April 24, 2023
From
Agenus
Via
Business Wire
Agenus Receives Fast Track Designation for Botensilimab and Balstilimab in Colorectal Cancer
April 17, 2023
From
Agenus Inc.
Via
Business Wire
Gain Therapeutics Appoints C. Evan Ballantyne as Chief Financial Officer
April 12, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Agenus Announces Dividend of 5 Million Shares of MiNK Therapeutics
March 30, 2023
From
Agenus Inc.
Via
Business Wire
Agenus’ Botensilimab in Combination with Balstilimab Shows 33% Durable Responses in Ovarian Cancer
March 27, 2023
From
Agenus Inc.
Via
Business Wire
Agenus Reports Fourth Quarter and Full Year 2022 Financial Results and Outlines 2023 Objectives
March 14, 2023
From
Agenus Inc.
Via
GlobeNewswire
Agenus Cancels Conference Call to Discuss the Company’s Minority Cash Holdings at SVB in Light of Government’s SVB Deposit Access Announcement
March 12, 2023
Conference Call Cancelled
From
Agenus Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.